Production (Stage)
Quoin Pharmaceuticals, Ltd.
QNRX
$8.74
$0.212.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.59% | -1.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 64.53% | -4.86% | |||
| Operating Income | -64.53% | 4.86% | |||
| Income Before Tax | -64.94% | 1.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -64.94% | 1.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -64.94% | 1.64% | |||
| EBIT | -64.53% | 4.86% | |||
| EBITDA | -65.21% | 4.91% | |||
| EPS Basic | 47.42% | 24.07% | |||
| Normalized Basic EPS | 47.42% | 24.07% | |||
| EPS Diluted | 47.61% | 24.56% | |||
| Normalized Diluted EPS | 47.42% | 24.07% | |||
| Average Basic Shares Outstanding | 213.70% | 29.52% | |||
| Average Diluted Shares Outstanding | 215.09% | 29.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||